Recent Quotes (30 days)

You have no recent quotes
chg | %

Verisante Technology Inc  

(Public, CVE:VRS)   Watch this stock  
Find more results for CVE:THZ
-0.010 (-9.09%)
Jan 30 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.10 - 0.10
52 week 0.08 - 0.25
Open 0.10
Vol / Avg. 7,000.00/133,518.00
Mkt cap 8.63M
P/E     -
Div/yield     -
EPS -0.05
Shares 86.30M
Beta 0.50
Inst. own     -

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -631.51%
Operating margin - -633.18%
EBITD margin - -496.54%
Return on average assets -58.68% -79.84%
Return on average equity -80.40% -90.79%
Employees 8 -
CDP Score - -


306-2309 41st Ave W
+1-604-6050507 (Phone)
+1-604-6050508 (Fax)

Website links


Verisante Technology, Inc. is a medical device company. The Company is engaged in commercializing systems for the early detection of cancer. The Company's product portfolios include Verisante Aura and Verisante Core. Verisante Aura is a non-invasive Raman spectroscopy system designed to aid medical professionals in the detection of skin cancer. The system provides valuable information by identifying spectral changes associated with the biochemistry of skin cancer cells in less than a second; providing immediate results. The Verisante Core series utilizes the platform technology behind the Verisante Aura for the early detection of other cancers including lung, colon and cervical, using an endoscopic attachment.

Officers and directors

Thomas A. Braun President, Chief Executive Officer, Chief Business Development Officer, Director
Anna Trinh Chief Financial Officer, Vice President - Administration, Corporate Counsel, Secretary
Joseph Biegel Independent Director
Karen Boodram Independent Director
Age: 49
Christopher John Wesley Dennis Independent Director
Jake J. Thiessen Ph.D. Independent Director
Age: 66